The August 11 operating report puts clinic growth, NeuroStar utilisation and cost discipline at the centre of the commercial TMS company’s next phase
MALVERN, Pennsylvania, August 11, 2026. Neuronetics reported second-quarter financial and operating results as it continues integrating its NeuroStar transcranial magnetic stimulation platform with the Greenbrook clinic network.
The combination gives Neuronetics exposure to both the installed technology and the delivery setting. That vertical model can create closer feedback between device use, clinician workflow, patient access and commercial execution, but it also increases the importance of clinic productivity and disciplined operating costs.
For interventional psychiatry, adoption depends on more than regulatory clearance. Providers must identify appropriate patients, secure reimbursement, schedule repeated treatment sessions and maintain trained teams. Small improvements in referral conversion, treatment completion or device utilisation can materially affect clinic economics.
The company’s operating update should therefore be read as an execution report rather than a single-quarter financial event. Investors and healthcare partners need to examine revenue quality, patient volumes, gross margin, cash use and whether growth is repeatable across locations.
The broader sector lesson is that neurotechnology commercialisation requires an integrated evidence and access model. Clinical outcomes, reimbursement, workforce design and site-level operations must reinforce one another if a device-based therapy is to scale reliably.
Neuronetics is a commercial-stage neurotechnology and healthcare company built around NeuroStar transcranial magnetic stimulation and the Greenbrook treatment-centre network. Its public reporting separates revenue associated with clinics, systems and treatment sessions. The model changed materially when Greenbrook became part of the company, so comparisons must distinguish reported growth from pro forma operating trends.
The company entered 2026 with guidance for annual revenue, gross margin, operating expense and operating cash flow. Its first-quarter release reported revenue of $34.5 million, including $21.5 million from US clinics, and lower cash use than the comparable prior-year period. The August 11 release provides the next checkpoint on that plan. Readers should use the official Q2 release and SEC filings for the exact current figures and reconciliations.
A device manufacturer usually earns revenue from capital equipment, service and consumables or treatment sessions. A clinic operator earns revenue by attracting eligible patients, obtaining authorisation, delivering care and collecting reimbursement. Combining the two creates a larger addressable revenue pool, but it also imports labour, rent, billing, scheduling and local marketing into the operating model.
That shift affects margin interpretation. Clinic revenue can grow while consolidated gross margin differs from a device-only profile. Management must show that the integrated model produces more durable patient flow, better utilisation and stronger cash generation than the companies could achieve separately. Revenue alone cannot answer that question.
The potential flywheel begins with awareness and referrals. More evaluated patients can lead to more completed TMS courses. Higher session volume can improve utilisation of installed systems and clinic staff. Better utilisation can spread fixed costs and generate outcomes data that supports additional referrals. In turn, a stronger provider network can make the platform more attractive to payers and clinicians. Each step can break if authorisation is slow, patients do not complete treatment, clinics lack staff or claims collection lags.
This is why operational measures matter. Investors should watch clinic same-site trends, new-patient starts, treatment sessions, system placement quality, average selling price, collection performance and cash conversion. A system shipped to a low-volume account may add near-term revenue but contribute less to recurring economics than a system placed where referral and treatment capacity are strong.
TMS has a recognised role in depression care, but access depends on coverage policies, clinician awareness and the ability of patients to attend a repeated-session treatment course. Expanding the types of qualified professionals who can order or supervise treatment may reduce one bottleneck in some settings. It does not automatically create demand or eliminate payer documentation requirements.
Greenbrook gives Neuronetics more control over the patient journey. That control can help the company test referral processes and standardise operations. It also means the company bears more responsibility when a clinic underperforms. Site selection, local physician relationships and revenue-cycle execution become as important as hardware innovation.
Commercial TMS companies can draw on clinical trials, regulatory clearances and real-world datasets. Those evidence types answer different questions. A controlled study can estimate treatment effect under a protocol. Registry data can show how care performs across broader practice settings but may include selection and reporting limitations. Regulatory clearance defines permitted marketing; it does not guarantee an individual outcome. Publication-quality communication should keep those boundaries visible.
For Neuronetics, ownership of a clinic network may increase access to operational and outcomes data. The analytical opportunity is valuable only if data definitions are consistent, missingness is understood and comparisons avoid overstating causality. Data governance and patient privacy must remain part of the commercial architecture.
The integrated model could become a defensible distribution advantage if Neuronetics demonstrates that clinics generate repeatable growth and improve system utilisation without consuming unsustainable cash. This is analysis based on the model, not a forecast from the company. The strongest evidence would be several quarters of comparable clinic performance, improving cash conversion and stable quality measures.
The principal risk is operational complexity. A business that sells sophisticated equipment and also runs treatment centres must excel at product support, clinical workflow, payer contracting, labour management and collections. Weakness in one area can obscure progress in another. Integration savings are useful, but cutting costs too quickly could damage patient acquisition or clinic capacity.
Interventional psychiatry is expanding the range of care beyond daily medicines and traditional psychotherapy. Its commercial success will depend on whether providers can embed technology into routine pathways without creating excessive burden for patients or clinicians. Neuronetics is effectively testing one answer: bring the technology and part of the delivery network under common ownership.
Other neurotechnology developers should watch the result. A strong outcome would support closer integration of devices, clinics and data. A weak outcome would suggest that partnerships or independent provider networks may preserve flexibility. Either way, the Q2 update matters because it provides a current operating test of how an evidence-backed neurotechnology becomes a scalable service.
Keep in touch with our news & offers
